How big is Relay Therapeutics, Inc.?

As of Jun 18, Relay Therapeutics, Inc. has a market capitalization of 524.62 million and reported net sales of 7.68 million with a net profit of -333.38 million over the latest four quarters. Shareholder's funds are 777.79 million, and total assets amount to 871.30 million.

As of Jun 18, Relay Therapeutics, Inc. has a market capitalization of 524.62 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 7.68 million, while the sum of net profit for the same period is -333.38 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 777.79 million, and total assets amount to 871.30 million.

What does Relay Therapeutics, Inc. do?

Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on drug discovery in oncology. As of March 2025, it reported net sales of $8 million and a net loss of $77 million, with a market cap of $524.62 million.

Overview: <BR>Relay Therapeutics, Inc. is a clinical-stage precision medicines company focused on transforming the drug discovery process in the pharmaceuticals and biotechnology industry, specifically targeting oncology.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 8 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -77 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 524.62 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.98 <BR>Return on Equity: -47.81% <BR>Price to Book: 0.73<BR><BR>Contact Details: <BR>Address: 399 Binney Street, 2Nd Floor, CAMBRIDGE MA : 02139 <BR>Tel: 1 617 3708837 <BR>Fax: 1 302 6555049 <BR>Website: https://relaytx.com/

Should I buy, sell or hold Relay Therapeutics, Inc.?

Who are in the management team of Relay Therapeutics, Inc.?

As of March 2022, the management team of Relay Therapeutics, Inc. includes Dr. Sanjiv Patel as President and CEO, with Dr. Mark Murcko on the Board of Directors alongside independent directors Mr. Alexis Borisy, Dr. Linda Hill, Mr. Douglas Ingram, and Dr. Christoph Lengauer.

As of March 2022, the management team of Relay Therapeutics, Inc. includes Dr. Sanjiv Patel, who serves as the President, Chief Executive Officer, and Director. Additionally, the Board of Directors features Dr. Mark Murcko as a Director, and several independent directors: Mr. Alexis Borisy, Dr. Linda Hill, Mr. Douglas Ingram, and Dr. Christoph Lengauer.

Is Relay Therapeutics, Inc. overvalued or undervalued?

As of November 2, 2023, Relay Therapeutics, Inc. is considered risky due to its negative financial metrics, including a Price to Book Value of 0.80, an EV to EBITDA ratio of 0.34, a troubling -47.81% Return on Equity, and a one-year return of -39.97%, significantly underperforming compared to the S&P 500's 17.14% return.

As of 2 November 2023, the valuation grade for Relay Therapeutics, Inc. has moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued given its negative performance metrics, including a Price to Book Value of 0.80 and an EV to EBITDA ratio of 0.34. Additionally, the Return on Equity (ROE) stands at a troubling -47.81%, reflecting significant losses relative to shareholder equity.<BR><BR>In comparison to its peers, Relay Therapeutics, Inc. has a less favorable EV to EBITDA ratio than Deciphera Pharmaceuticals, Inc. at -9.7157 and Tango Therapeutics, Inc. at -3.7404, further underscoring its relative weakness in valuation. Despite a recent uptick in stock price, the company's one-year return of -39.97% starkly contrasts with the S&P 500's 17.14% return, reinforcing the notion that Relay Therapeutics is struggling significantly compared to broader market performance.

Is Relay Therapeutics, Inc. technically bullish or bearish?

As of October 3, 2025, Relay Therapeutics, Inc. shows a bullish technical trend, supported by bullish MACD and moving averages, despite mixed signals from the weekly RSI and Dow Theory indicating a mildly bullish outlook.

As of 3 October 2025, the technical trend for Relay Therapeutics, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, supported by bullish signals from both the Bollinger Bands and KST. However, the weekly RSI indicates a bearish stance, while the monthly RSI shows no signal. Daily moving averages are bullish, and Dow Theory reflects a mildly bullish outlook on both weekly and monthly time frames. Overall, the current technical stance is bullish, albeit with some mixed signals in the weekly indicators. Multi-period return data is not available for comparison with the S&P 500.